Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2
Sienna Biopharmaceuticals Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis
REPEAT - Drilling at Swanson Gold Deposit Confirms Large-Scale Gold Discovery with 1.18 g/t Au over 255.04 metres and 1.65 g/t Au over 136.01 metres
